XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.4
SEGMENT AND GEOGRAPHIC AREA INFORMATION (Tables)
12 Months Ended
Sep. 30, 2024
SEGMENT AND GEOGRAPHIC AREA INFORMATION  
Schedule of information regarding operations by segment

Information regarding operations by segment for the twelve- month period ended September 30, 2024 is as follows:

Therapeutic DNA

MDx Testing

DNA Tagging and

    

Production

    

Services 

    

Security Products

    

Consolidated

Revenues:

 

  

 

  

 

  

 

  

Product revenues

$

560,000

$

$

514,813

$

1,074,813

Service revenues

 

335,354

703,323

1,038,677

Clinical laboratory service revenues

 

1,330,850

1,330,850

Less intersegment revenues

 

(12,920)

(12,920)

Total revenues

$

895,354

$

1,317,930

$

1,218,136

$

3,431,420

Gross profit

$

678,166

$

(49,830)

$

388,543

$

1,016,879

(Loss) income from segment operations (a)

$

(4,789,268)

$

(1,489,220)

$

(2,551,983)

$

(8,830,471)

Information regarding operations by segment for the twelve- month period ended September 30, 2023 is as follows:

Therapeutic DNA

MDx Testing

DNA Tagging and

    

Production

    

Services 

    

Security Products

    

Consolidated

Revenues:

Product revenues

$

560,000

$

$

658,185

$

1,218,185

Service revenues

 

506,285

490,581

996,866

Clinical laboratory service revenues

 

11,253,312

11,253,312

Less intersegment revenues

 

(100,920)

(100,920)

Total revenues

$

1,066,285

$

11,152,392

$

1,148,766

$

13,367,443

Gross profit

$

748,940

$

4,409,186

$

375,306

$

5,533,432

(Loss) income from segment operations (a)

$

(3,792,871)

$

1,206,652

$

(3,550,794)

$

(6,137,013)

Schedule of reconciliation of segment loss from operations to corporate (loss) income

September 30,

    

2024

2023

Loss from operations of reportable segments

    

$

(8,830,471)

    

$

(6,137,013)

General corporate expenses (b)

 

(5,194,294)

 

(4,816,277)

Interest income

 

176,301

 

75,332

Unrealized gain on change in fair value of warrants classified as a liability

9,430,000

Unrealized loss on change in fair value of warrants classified as a liability - warrant modification

(394,000)

Transaction costs allocated to registered direct offering

(633,198)

854,400

Transaction costs allocated to warrant liabilities

Loss on issuance of warrants

(1,633,767)

Other income (expense), net

 

(8,877)

$

642

Consolidated loss before provision for income taxes

$

(7,088,306)

$

(10,022,916)

(a)

Segment operating loss consists of net sales less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

(b)

General corporate expenses consists of Selling, general and administrative expenses that are not specifically identifiable to a segment.

Schedule of net revenues by geographic location of customers

Year Ended September 30, 

    

2024

    

2023

Americas

$

2,269,826

$

12,222,650

Europe

 

172,368

258,355

Asia and other

 

989,226

886,438

Total

$

3,431,420

$

13,367,443